Ładuje się......
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
PURPOSE: Blocking the interaction between the programmed cell death (PD)-1 protein and one of its ligands, PD-L1, has been reported to have impressive antitumor responses. Therapeutics targeting this pathway are currently in clinical trials. Pembrolizumab and nivolumab are the first of this anti-PD-...
Zapisane w:
| Wydane w: | Clin Ther |
|---|---|
| Główni autorzy: | , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2015
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4497957/ https://ncbi.nlm.nih.gov/pubmed/25823918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.02.018 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|